Your browser doesn't support javascript.
loading
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.
Echevarría-Vargas, Ileabett M; Reyes-Uribe, Patricia I; Guterres, Adam N; Yin, Xiangfan; Kossenkov, Andrew V; Liu, Qin; Zhang, Gao; Krepler, Clemens; Cheng, Chaoran; Wei, Zhi; Somasundaram, Rajasekharan; Karakousis, Giorgos; Xu, Wei; Morrissette, Jennifer Jd; Lu, Yiling; Mills, Gordon B; Sullivan, Ryan J; Benchun, Miao; Frederick, Dennie T; Boland, Genevieve; Flaherty, Keith T; Weeraratna, Ashani T; Herlyn, Meenhard; Amaravadi, Ravi; Schuchter, Lynn M; Burd, Christin E; Aplin, Andrew E; Xu, Xiaowei; Villanueva, Jessie.
Afiliación
  • Echevarría-Vargas IM; Molecular & Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
  • Reyes-Uribe PI; Molecular & Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
  • Guterres AN; Molecular & Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
  • Yin X; Molecular & Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
  • Kossenkov AV; Molecular & Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
  • Liu Q; Molecular & Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
  • Zhang G; Molecular & Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
  • Krepler C; Molecular & Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
  • Cheng C; College of Computing Sciences, New Jersey Institute of Technology, Newark, NJ, USA.
  • Wei Z; College of Computing Sciences, New Jersey Institute of Technology, Newark, NJ, USA.
  • Somasundaram R; Molecular & Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
  • Karakousis G; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Xu W; Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Morrissette JJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
  • Lu Y; Center for Personalized Diagnostics, Hospital of the University of Pennsylvania University of Pennsylvania, Philadelphia, PA, USA.
  • Mills GB; Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Sullivan RJ; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Benchun M; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Frederick DT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Boland G; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Flaherty KT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Weeraratna AT; Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
  • Herlyn M; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Amaravadi R; Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.
  • Schuchter LM; Immunology, Microenvironment and Metastasis Program, The Wistar Institute, Philadelphia, PA, USA.
  • Burd CE; Molecular & Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA, USA.
  • Aplin AE; Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.
  • Xu X; Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
  • Villanueva J; Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
EMBO Mol Med ; 10(5)2018 05.
Article en En | MEDLINE | ID: mdl-29650805
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Proteínas / Resistencia a Antineoplásicos / Ensayos Antitumor por Modelo de Xenoinjerto / MAP Quinasa Quinasa 1 / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: EMBO Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Proteínas / Resistencia a Antineoplásicos / Ensayos Antitumor por Modelo de Xenoinjerto / MAP Quinasa Quinasa 1 / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: EMBO Mol Med Asunto de la revista: BIOLOGIA MOLECULAR Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido